CanBas Co

CanBas Co OCF Growth YoY

The Year-over-Year Operating Cash Flow Growth of CanBas Co (4575.T) as of Nov 14, 2026 is -84.59 %. In the previous year, Year-over-Year Operating Cash Flow Growth was 39.74 % — a change of -312.85% (lower).

OCF Growth YoY

-84.59 %

YoY

-312.85%

Last updated:

Year-over-Year Operating Cash Flow Growth of CanBas Co is 2026 -84.59 % . Year-over-Year Operating Cash Flow Growth of CanBas Co was 2025 39.74 % . It decreases by -312.85% lower compared to the previous year.

The CanBas Co OCF Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Growth YoY
Date
OCF Growth YoY
Jan 1, 2019
10.72 JPY
Jan 1, 2020
-44.37 JPY
Jan 1, 2021
-24.53 JPY
Jan 1, 2022
-4.54 JPY
Jan 1, 2023
-94.35 JPY
Jan 1, 2024
8.49 JPY
Jan 1, 2025
39.74 JPY
Jan 1, 2026
-84.59 JPY
The CanBas Co OCF Growth YoY history
YEAROCF Growth YoYYoY
-84.59 %-312.85%
39.74 %+368.17%
8.49 %-109.00%
-94.35 %+1,979.40%
-4.54 %-81.51%
-24.53 %-44.70%
-44.37 %-513.76%
10.72 %-128.93%
-37.06 %-248.32%
24.99 %-171.32%
-35.04 %+48.45%
-23.60 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co., Ltd. generates revenue through pharmaceutical research and development, focusing on basic anticancer drug discovery and early clinical development. The company develops drug discovery concepts, selects candidate compounds, conducts simple animal studies, and analyzes basic data on anticancer drug candidates entering development. It also performs preclinical studies for clinical trial applications and manages the initial phase of clinical trials. The primary buyers of these services are pharmaceutical companies seeking to advance their anticancer drug pipelines through early-stage research and development. CanBas Co., Ltd. operates with a team of 12 full-time employees, specializing in anticancer drug research. The company's services are tailored for pharmaceutical firms requiring expertise in early-stage drug development, particularly in the discovery and preclinical phases. Its focus on basic anticancer drug research and early clinical development positions it as a specialized provider in the pharmaceutical R&D sector. The firm's business model relies on providing comprehensive research services to pharmaceutical companies, including concept development, compound selection, animal studies, and data analysis. These services are critical for pharmaceutical firms to progress anticancer drug candidates from discovery to early clinical stages, ensuring efficient and effective development pathways for new treatments. CanBas Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CanBas Co stock

Year-over-Year Operating Cash Flow Growth of CanBas Co is -84.59 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Operating Cash Flow Growth CanBas Co since 2006 – with annual values, charts, and detailed analysis.

OCF growth measures the percentage change in operating cash flow. Growing OCF indicates improving cash generation from core operations.

To evaluate Year-over-Year Operating Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Operating Cash Flow Growth.

Year-over-Year Operating Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Operating Cash Flow Growth's CanBas Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — CanBas Co

All Key Metrics — CanBas Co